Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.

ABSTRACT:

Background

Hydroxyurea is the primary treatment for sickle cell anemia (SCA), yet real-world implementation in high-income settings is suboptimal. Variation in prescribed hydroxyurea dose and patient adherence in these settings can both affect actual exposure to hydroxyurea. Quantifying the contributions of hydroxyurea dose and medication adherence to the relationship between hydroxyurea exposure and hematologic parameters could inform strategies to optimize exposure and improve outcomes.

Procedure

We evaluated the relationship between hydroxyurea exposure, defined by average prescribed dose and adherence, and hematologic parameters using data from children with SCA who were enrolled in two prospective hydroxyurea adherence studies. Hydroxyurea adherence was assessed by vide

SUBMITTER: Creary SE 

PROVIDER: S-EPMC9038671 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature